INSULET CORP
Nasdaq: PODD·Acton, Massachusetts·CIK 0001145197
- Price
- $145.29
- Base IV
- $150.52
Valuation snapshot
At $145.29, the price sits between our bear case ($90.74) and base case ($150.52).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $150.52
- above today's price · range $90.74–$207.07
- Price vs base case
- 3% below
- $145.29 against $150.52
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 12.0% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $90.74 to bull $207.07. Values per share.
Price against each value
- Bear case
- $90.74
- Price 60% above
- No growth
- …
- —
- Base case
- $150.52
- Price 3% below
What does Insulet do?
Insulet manufactures wearable, tubeless insulin pods that automatically deliver insulin to people with diabetes, eliminating the need for multiple daily needle injections and external tubing.
It brought in $3.2B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Acton, Massachusetts
- Trades on
- Nasdaq as PODD
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 13¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 42¢ of every dollar.
- Making what it sells28¢
- Research and development11¢
- Sales, marketing and admin42¢
- Interest and other costs1¢
- Tax4¢
- Left as profit13¢
Who pays Insulet, and for what?
Insulet makes the Omnipod, a small tubeless insulin pump that sticks to the skin and is thrown away after up to three days. Most of its money comes from repeat sales of these disposable Pods to people with diabetes who use insulin. It also makes a modified pod that Amgen uses to deliver a chemotherapy-support drug.
Most US sales go to three large wholesalers that supply pharmacies and together made up about 78% of 2025 revenue; the bill is mostly paid by private insurers and government programs like Medicare and Medicaid, and outside the US it sells through distributors or straight to users.
U.S. Omnipod
71%Omnipod 5 and Omnipod DASH insulin pods and controllers sold in the United States, mainly through pharmacies.
International Omnipod
28%Omnipod products sold in about 24 other countries, mainly in Europe, the Middle East, Canada and Australia.
Drug Delivery
1%Custom pods made for Amgen's Neulasta Onpro kit, which helps lower infection risk after chemotherapy. The supply agreement runs to December 2028.
Where its work physically happens, beyond headquarters:
- Insulet Malaysia Omnipod manufacturing plant — Johor Bahru, Malaysia. Insulet owns this 400,000 sq ft automated Omnipod plant, about twice the size of its Acton factory. Production began in June 2024, and the plant is now a core source of the capacity and gross-margin scale behind global Omnipod growth.
- Contract-manufactured Omnipod facility (China) — Kunshan, China. A third-party contract manufacturer runs Omnipod production lines here for Insulet. That makes it a source of supply diversification, but also a concentration and tariff risk outside Insulet's own plants.
- Insulet Costa Rica Omnipod plant (under development) — Heredia, Costa Rica. This is Insulet's third owned Omnipod plant and its first in Latin America. It is a reported ~US$200M investment, and the IFC has proposed US$97M of construction financing. It will add future pod capacity and geographic redundancy.
How is the business doing?
Sales grew from $904.4M in 2020 to $2.7B in 2025, about 25% a year.
Running the business leaves about 18¢ of each sales dollar as operating profit, up from 6¢ in 2020.
After paying for its upkeep and new investment, it had $260M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Insulet says it exists to transform the lives of people with diabetes by making insulin delivery simpler and less of a burden.
“Born of empathy, driven by ingenuity, proven by science, we transform the lives of people with diabetes.”
What management says it is working on now:
Bringing Omnipod 5 to more countries
Omnipod 5 launched in nine more countries in 2025 and in several Middle East countries in early 2026, reaching 19 countries. The company is building international teams and working on pricing and insurance coverage to enter more markets.
Insulet 10-K for fiscal 2025, Item 7Growing among people with type 2 diabetes
Omnipod 5 was cleared in the US for adults with type 2 diabetes in 2024. The company dropped a simpler product (Omnipod GO) so it could focus on Omnipod 5 for this group.
Insulet 10-K for fiscal 2025, Item 7Next-generation products
Work in progress includes linking Omnipod 5 with Abbott's Libre 3 Plus sensor, Omnipod 6 (its next automated system, whose main trial finished in 2025), and a fully automated system for type 2 diabetes.
Insulet 10-K for fiscal 2025, Item 1Adding manufacturing capacity
The company makes Pods in Massachusetts and Malaysia and on lines in China. It is building a third plant in Costa Rica and expects spending on equipment and buildings in 2026 to be higher than in 2025.
Insulet 10-K for fiscal 2025, Item 7Growing while staying profitable, and buying back shares
Management describes its financial goal as sustaining profitable growth. In February 2026 the board approved $350 million more for buying back the company's own shares, and the company planned to use $300 million of that in early 2026.
Insulet 10-K for fiscal 2025, Item 7
- Total revenue growth (constant currency), Full year 2026
- 20%–22% (lowered in August 2026)
- Insulet Reports Second Quarter 2026 Results
- U.S. Omnipod revenue growth, Full year 2026
- 17%–19% (cut from 20%–22%)
- Insulet Reports Second Quarter 2026 Results
- International Omnipod revenue growth, Full year 2026
- 30%–32% (raised)
- Insulet Reports Second Quarter 2026 Results
- Revenue growth per year (constant currency), 2025 to 2028
- About 20% on average
- Insulet Outlines Long Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
- Adjusted operating margin, Each year through 2028, including 2026
- About +1 percentage point each year
- Insulet Outlines Long Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
- Adjusted earnings per share growth, 2025 to 2028
- 25% or more per year on average
- Insulet Outlines Long Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
What's changing right now?
Growth is slowing. In Q3 2026 it sold 19% more than a year earlier. The year before, quarters averaged 30%.
Its operating margin is wider than a year ago: 23¢ per sales dollar, against 17¢.
Since Oct 2026 the share price has fallen 5%, from $152.50 to $145.29.
Recently
December 31, 2025
Annual Capital Expenditures as % of Revenue changed to 7.1%
Insulet Corp 2025 Form 10-K Consolidated Statements of Cash FlowsDecember 31, 2025
Annual Gross Margin changed to 71.6%
Insulet Corp 2025 Form 10-KDecember 31, 2025
Global Active Omnipod Customers changed to 600000 number
Insulet Reports Fourth Quarter and Full Year 2025 Results
Coming up
November 4, 2026
Third-quarter 2026 results
Insulet will report results for July to September 2026 and may update its 2026 outlook after cutting its US growth forecast in August.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026December 2026
Glooko data agreement expires
The partnership that lets Omnipod users and doctors view data in Glooko's system ends in December 2026. Insulet launched its own data platform, Omnipod Discover, in 2026.
Insulet 10-K for fiscal 2025, Item 1AExpected; date not stated
Omnipod 5 with Abbott Libre 3 Plus
The company is preparing a full launch of Omnipod 5 working with Abbott's Libre 3 Plus sensor, which would give users more sensor choice. No exact date has been given.
Insulet 10-K for fiscal 2025, Item 7Trial start 2026; filing reportedly planned for 2027
Fully automated system for type 2 diabetes
Insulet planned to start the main US trial in 2026 for a system that doses insulin without user input for people with type 2 diabetes. Coverage of its August 2026 call mentions a planned filing with regulators in 2027, but this comes from a secondary summary and is not confirmed in the filing.
Insulet 10-K for fiscal 2025, Item 1
Our own estimate moved too: the base case went from $126.50 to $150.52 a share between our last two valuations. The biggest reason: Annual Capital Expenditures as % of Revenue moved from an unreported prior value to 7.1%, as reported in Insulet Corp 2025 Form 10-K Consolidated Statements of Cash Flows.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Keeping users, especially type 2
Nearly all revenue comes from Omnipod, and growth depends on people staying on it. In August 2026 the company lowered its US outlook because fewer type 2 users stayed on the product than it expected.
From the company's own filingsWould hit how fast sales growInsulet Reports Second Quarter 2026 Results
Competition and cheaper alternatives
Insulet competes with pump makers such as Medtronic, Tandem and Beta Bionics, and with insulin pens and injections, which can cost much less. New products or price cuts by rivals could slow sales or push prices down.
From the company's own filingsWould hit how fast sales growInsulet 10-K for fiscal 2025, Item 1A
Depends on insurers and government payment
Sales depend on insurers and government health systems paying most of the price. Insurers can end contracts, and US healthcare law changes or price pressure abroad could reduce demand or prices.
From the company's own filingsWould hit how much of each sale it keepsInsulet 10-K for fiscal 2025, Item 1A
Possible tariffs on medical devices
A US government investigation could remove the tariff exemption that now covers some medical devices. The company makes products in Malaysia and China and says new tariffs would have a material impact on results in future years.
From the company's own filingsWould hit how much of each sale it keepsInsulet 10-K for fiscal 2025, Item 1A and Item 7
Few factories, suppliers and partners
Products are made in three places, and some parts come from only one supplier. Omnipod 5 also needs agreements with Dexcom and Abbott to work with their glucose sensors. Losing any of these could interrupt supply.
From the company's own filingsWould hit how much it has to reinvestInsulet 10-K for fiscal 2025, Item 1A
New treatments could shrink the market
Weight-loss and diabetes drugs (GLP-1s) may delay type 2 diabetes from getting worse, and companies such as Vertex are working on possible cures. Major advances could make insulin pumps less needed.
From the company's own filingsWould hit its growth in the long runInsulet 10-K for fiscal 2025, Item 1A
Revenue growth was 19.2% in Q3 2026 compared to 33.9% in Q1 2026, indicating normal deceleration as revenue scale exceeds $3 billion annually.
From our researchWould hit how fast sales growInsulet Quarterly Financial Results (Q1-Q3 2026)
Is it a good business?
From 2016 to 2025 it earned between -3% and 21% on the capital invested in it, a median of 5%. Its cost of capital in the latest valuation is 9.0%; returns were above it in 4 of the 10 years.
From 2016 to 2025 it earned between -46% and 35% on its shareholders' equity, a median of 2%.
Over 10 years its operating margin ranged from 3¢ to 17¢ per sales dollar, a median of 6¢. Gross margin ran from 58¢ to 72¢.
Cost of capital 9.0%
It bought back shares: the count fell 1.7% in a year, so each remaining share owns a slightly bigger slice.
It owes $377.7M more than it holds in cash, about 0.6 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $145.29. Our put its value between $90.74 and $207.07, with $150.52 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $90.74
This scenario envisions annual sales growth cooling sharply from recent thirty percent rates down to the mid-single digits as competition intensifies and market saturation sets in, while company profitability levels off near recent performance.
Base case, $150.52
This scenario envisions sales growth moderating steadily from recent twenty to thirty percent rates down toward high single digits as international adoption continues, allowing the business to modestly expand its profitability beyond recent record levels.
Bull case, $207.07
This scenario envisions the company maintaining rapid double-digit sales expansion well above historical industry averages by capturing the vast adult Type 2 diabetes population, propelling overall profitability to new all-time highs.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price and our value are close.Margin of safety: 3%
For Insulet to be worth today's $145.29, sales would need to grow about 12.3% a year. We assume 13.0%. Over the last 5 years, sales grew 25.7% a year.
Or, if sales grow 13.0% as we assume, the price works with a profit margin of 21.3% (we assume 22.0%).
Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.
Do you think sales can grow 12.3% a year?
Try your own numbersWe're moderately sure of this range: it scores 71 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $150.52 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average13.0%
- Operating margin22.0%
- Long-term growth rate3.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$150.52 3.6%


